Regulation of N6 -methyladenosine modification in erythropoiesis and thalassemia

Clin Genet. 2024 Mar 15. doi: 10.1111/cge.14518. Online ahead of print.

Abstract

In eukaryotic RNA, N6 -methyladenosine (m6 A) is a prevalent form of methylation modification. The m6 A modification process is reversible and dynamic, written by m6 A methyltransferase complex, erased by m6 A demethylase, and recognized by m6 A binding proteins. Through mediating RNA stability, decay, alternative splicing, and translation processes, m6 A modification regulates gene expression at the post-transcriptional level. Erythropoiesis is the process of hematopoietic stem cells undergoing proliferation, a series of differentiation and maturation to form red blood cells (RBCs). Thalassemia is a common monogenic disease characterized by excessive production of ineffective RBCs in the peripheral circulation, resulting in hemolytic anemia. Increasing evidence suggests that m6 A modification plays a crucial role in erythropoiesis. In this review, we comprehensively summarize the function of m6 A modification in erythropoiesis and further generalize the mechanism of m6 A modification regulating ineffective erythropoiesis and fetal hemoglobin expression. The purpose is to improve the understanding of the pathogenesis of erythroid dysplasia and offer new perspectives for the diagnosis and treatment of thalassemia.

Keywords: N6-methyladenosine; erythropoiesis; fetal-hemoglobin; gene expression; thalassemia.

Publication types

  • Review